CA2772618C - Fatty acid niacin conjugates and their uses - Google Patents

Fatty acid niacin conjugates and their uses Download PDF

Info

Publication number
CA2772618C
CA2772618C CA2772618A CA2772618A CA2772618C CA 2772618 C CA2772618 C CA 2772618C CA 2772618 A CA2772618 A CA 2772618A CA 2772618 A CA2772618 A CA 2772618A CA 2772618 C CA2772618 C CA 2772618C
Authority
CA
Canada
Prior art keywords
compound
alkyl
independently
docosa
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2772618A
Other languages
English (en)
French (fr)
Other versions
CA2772618A1 (en
Inventor
Jill C. Milne
Michael R. Jirousek
Jean E. Bemis
Chi B. Vu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astria Therapeutics Inc
Original Assignee
Catabasis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2772618(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Catabasis Pharmaceuticals Inc filed Critical Catabasis Pharmaceuticals Inc
Publication of CA2772618A1 publication Critical patent/CA2772618A1/en
Application granted granted Critical
Publication of CA2772618C publication Critical patent/CA2772618C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2772618A 2009-09-01 2010-08-31 Fatty acid niacin conjugates and their uses Expired - Fee Related CA2772618C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23890309P 2009-09-01 2009-09-01
US61/238,903 2009-09-01
US30852410P 2010-02-26 2010-02-26
US61/308,524 2010-02-26
US31095210P 2010-03-05 2010-03-05
US61/310,952 2010-03-05
PCT/US2010/047262 WO2011028689A1 (en) 2009-09-01 2010-08-31 Fatty acid niacin conjugates and their uses

Publications (2)

Publication Number Publication Date
CA2772618A1 CA2772618A1 (en) 2011-03-10
CA2772618C true CA2772618C (en) 2018-08-21

Family

ID=43625772

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2772618A Expired - Fee Related CA2772618C (en) 2009-09-01 2010-08-31 Fatty acid niacin conjugates and their uses

Country Status (24)

Country Link
US (13) US8304551B2 (member.php)
EP (1) EP2473045B1 (member.php)
JP (1) JP5802209B2 (member.php)
KR (1) KR101685734B1 (member.php)
CN (1) CN102724877B (member.php)
AR (1) AR078151A1 (member.php)
AU (1) AU2010289683C1 (member.php)
BR (1) BR112012004677A2 (member.php)
CA (1) CA2772618C (member.php)
CL (1) CL2010000935A1 (member.php)
CR (1) CR20120167A (member.php)
DK (1) DK2473045T3 (member.php)
ES (1) ES2599626T3 (member.php)
GT (1) GT201200056A (member.php)
IL (1) IL218417A (member.php)
IN (1) IN2012DN02661A (member.php)
MX (1) MX2012002710A (member.php)
MY (1) MY158504A (member.php)
NI (1) NI201200038A (member.php)
NZ (1) NZ599067A (member.php)
RU (1) RU2569063C2 (member.php)
SG (2) SG178948A1 (member.php)
TW (1) TWI519312B (member.php)
WO (1) WO2011028689A1 (member.php)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
RU2489145C1 (ru) 2009-04-29 2013-08-10 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтические композиции, содержащие ера и сердечно-сосудистое средство, и способ их применения
NZ618734A (en) 2009-05-08 2015-01-30 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
MX338324B (es) 2009-06-15 2016-04-12 Amarin Pharma Inc Composiciones y metodos para reducir trigliceridos sin elevar los niveles de ldl-c en un sujeto en terapia de estatina concomitante.
IN2012DN02661A (member.php) 2009-09-01 2015-09-11 Catabasis Pharmaceuticals Inc
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
SG10201509127YA (en) 2010-11-05 2015-12-30 Pronova Biopharma Norge As Methods of treatment using lipid compounds
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2949344A3 (en) 2011-03-18 2016-01-13 Catabasis Pharmaceuticals, Inc. Use of intracellular enzymes for the release of covalently linked bioactives
EP2751071B1 (en) * 2011-08-31 2019-11-27 Jill C. Milne Fatty acid amides, compositions and methods of use
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
PT2800563T (pt) 2012-01-06 2018-11-07 Chrysalis Pharma Ag Composições enriquecidas com dpa de ácidos gordos omega-3 polinsaturados sob a forma de ácido livre
MX2014013150A (es) * 2012-05-01 2015-05-11 Catabasis Pharmaceuticals Inc Conjugados de acidos grasos de estatina y agonistas fxr, composiciones y metodos de uso.
WO2013169797A1 (en) 2012-05-07 2013-11-14 Omthera Pharmaceuticals, Inc. Compositions of statins and omega-3 fatty acids
BR112014029245A2 (pt) * 2012-05-25 2017-06-27 Catabasis Pharmaceuticals Inc métodos para diminuir a proteína convertase subtilisina/quexina tipo 9 (pcsk9)
WO2013187673A1 (ko) * 2012-06-11 2013-12-19 주식회사 휴메딕스 복합 비타민 컨쥬게이트 및 그를 포함하는 항산화제
EA039108B1 (ru) 2012-06-29 2021-12-06 Амарин Фармасьютикалз Айрлэнд Лимитед Способы уменьшения риска развития сердечно-сосудистого события у субъекта, получающего терапию статином
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
WO2014068463A2 (en) * 2012-11-03 2014-05-08 Mahesh Kandula Compositions and methods for the treatment of inflammation and metabolic disorders
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
CN103007081B (zh) * 2012-11-27 2013-12-04 鞠法红 一种治疗非酒精性脂肪肝的中药组合物
WO2014083476A2 (en) * 2012-11-27 2014-06-05 Mahesh Kandula Compositions and methods for the treatment of metabolic and lipid disorders
WO2014087307A2 (en) * 2012-12-04 2014-06-12 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome and diabetes
CN103012419B (zh) * 2012-12-20 2015-01-07 中国科学院深圳先进技术研究院 一种罗丹明b衍生物的合成方法
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
WO2014106804A2 (en) * 2013-01-04 2014-07-10 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014106805A2 (en) * 2013-01-05 2014-07-10 Mahesh Kandula Fatty acid conjugates and their uses
AU2014203872A1 (en) * 2013-01-07 2015-07-09 Catabasis Pharmaceuticals, Inc. Use of fatty acid niacin conjugates for treating diseases
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
WO2014122575A2 (en) * 2013-02-08 2014-08-14 Mahesh Kandula Fatty acid conjugates for the treatment of inflammation and metabolic diseases
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US20160287712A1 (en) * 2013-11-15 2016-10-06 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
MA41031A (fr) * 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016130417A1 (en) * 2015-02-11 2016-08-18 Omthera Pharmaceuticals Inc Omega-3 fatty acid prodrug compounds and uses thereof
WO2016173923A1 (en) 2015-04-28 2016-11-03 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
WO2018129403A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
CA3068254A1 (en) 2017-06-20 2018-12-27 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
US11925614B2 (en) 2017-12-06 2024-03-12 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
JP7517992B2 (ja) 2018-03-23 2024-07-17 ヤンセン ファーマシューティカ エヌ．ベー． 化合物及びその使用
BR112020024695A2 (pt) 2018-06-05 2021-03-02 Flagship Pioneering Innovations V, Inc agentes ativos e métodos de uso destes para o tratamento de distúrbios metabólicos e doença hepática gordurosa não alcoólica
RS65750B1 (sr) 2018-09-24 2024-08-30 Amarin Pharmaceuticals Ie Ltd Postupci smanjenja rizika od kardiovaskularnih događaja kod pacijenta
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US11767314B2 (en) 2018-11-02 2023-09-26 Conopco, Inc. Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
JP2023538626A (ja) * 2020-08-18 2023-09-08 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Ｎ－アシルアミノ酸製品および使用
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036951A (en) 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
US4169923A (en) * 1974-10-15 1979-10-02 Paolo Ferruti High polymers containing nicotinic acid, process for their preparation and their use
CA1113486A (en) 1977-04-01 1981-12-01 Alfred Halpern Ultra-violet filtration with certain aminosalicylic acid esters
US4264517A (en) 1978-12-11 1981-04-28 G.D. Searle & Co. Alkylphenyl 5Z,8Z,11Z,14Z,17Z-eicosapentaenoates
US4619938A (en) * 1984-03-21 1986-10-28 Terumo Kabushiki Kaisha Fatty acid derivatives of aminoalkyl nicotinic acid esters and platelet aggregation inhibitors
IT1196348B (it) 1984-11-29 1988-11-16 Italfarmaco Spa Composti ad attivita'antiinfiammatoria
JPS61204171A (ja) 1985-03-06 1986-09-10 Terumo Corp ５−フルオロウラシル誘導体およびこれを含有する医薬製剤
JPH0248545B2 (ja) 1985-10-30 1990-10-25 Terumo Corp 33pirijinkarubonsann11okishidojudotaioyobikoreoganjusuruketsushobangyoshuyokuseizai
JPS62106080A (ja) 1985-11-01 1987-05-16 Terumo Corp エタノ−ルアミン誘導体およびこれを含有する抗高脂血症剤
JPS62106019A (ja) * 1985-11-01 1987-05-16 Terumo Corp 抗高脂血症剤
JPS62258362A (ja) * 1986-05-02 1987-11-10 Terumo Corp アミド誘導体およびこれを含有する５−リポキシゲナ−ゼ作用阻害剤
US4670465A (en) 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
JPH01121253A (ja) 1987-11-05 1989-05-12 Terumo Corp エタノールアミン誘導体包接化合物およびその製法
US5760261A (en) 1990-02-28 1998-06-02 Guttag; Alvin Higher fatty acid derivatives of salicylic acid and salts thereof
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
GB9508023D0 (en) 1995-04-20 1995-06-07 Scotia Holdings Plc Fatty acid derivatives
AU713045B2 (en) * 1995-05-01 1999-11-25 Scarista Limited Nicotinic acid esters and pharmaceutical compositions containing them
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
GB9622636D0 (en) 1996-10-30 1997-01-08 Scotia Holdings Plc Presentation of bioactives
US5728732A (en) 1996-11-27 1998-03-17 Elizabeth Arden Company, Division Of Conopco, Inc. Skin treatment with salicylic acid esters and retinoids
PL336148A1 (en) 1997-04-04 2000-06-05 Pfizer Prod Inc Nicotinamide derivatives
CA2339018A1 (en) 1998-08-07 2000-02-17 Applied Research Systems Ars Holding N.V. Fsh mimetics for the treatment of infertility
EP1153049B1 (en) * 1999-01-29 2005-08-10 Amersham Biosciences KK Temperature-responsive polymer compound and process for producing the same
GB9930026D0 (en) 1999-12-21 2000-02-09 Univ Sheffield Novel compounds of unsaturated fatty acids
CA2398182C (en) 2000-01-31 2007-03-13 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
US6562995B1 (en) * 2000-12-21 2003-05-13 Beacon Laboratories, Inc. Delta dicarbonyl compounds and methods for using the same
DE60235535D1 (de) * 2001-01-19 2010-04-15 Inst Pharm & Toxicology Amms Aminderivat mit kaliumkanalregulierender funktion, dessen herstelung und verwendung
CZ20031895A3 (cs) 2001-01-31 2004-08-18 Pfizeráproductsáinc Nikotinamidové biarylové deriváty užitečné jako inhibitory isozymů PDE
EP1461014B1 (en) * 2001-12-04 2021-07-14 Ben Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US20040191278A1 (en) 2003-03-31 2004-09-30 Christensen Flemming Kjaergaar Topical agent for application to the skin prior to luminous treatment
JP2006523719A (ja) * 2003-04-18 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４抑制剤としてのピラゾール誘導体
US20050267091A1 (en) 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses
US20060105021A1 (en) * 2004-09-24 2006-05-18 Remington Direct Lp Cholesterol-reducing liquid
BRPI0516803A (pt) 2004-11-19 2008-09-23 Martek Biosciences Corp oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
WO2006113150A1 (en) 2005-04-13 2006-10-26 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007116027A1 (en) 2006-04-12 2007-10-18 Unilever Plc Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
BRPI0913425A2 (pt) 2008-06-02 2015-11-24 Reddys Lab Ltd Dr formulações de niacina com liberação modificada
NZ590179A (en) 2008-07-08 2012-12-21 Catabasis Pharmaceuticals Inc Fatty acid acetylated salicylates, diflunisal or triflusal and their uses
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
US20110009628A1 (en) 2009-07-08 2011-01-13 Haiyan Liu Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
IN2012DN02661A (member.php) 2009-09-01 2015-09-11 Catabasis Pharmaceuticals Inc
US9216224B2 (en) 2010-03-05 2015-12-22 Catabasis Pharmaceuticals, Inc. Fatty acid COX inhibitor derivatives and their uses
US20130045939A1 (en) 2010-03-19 2013-02-21 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
EP2949344A3 (en) 2011-03-18 2016-01-13 Catabasis Pharmaceuticals, Inc. Use of intracellular enzymes for the release of covalently linked bioactives
US20120252810A1 (en) 2011-04-04 2012-10-04 Catabasis Pharmaceuticals, Inc. Fatty acid non-flushing niacin derivatives and their uses
MX2014013150A (es) 2012-05-01 2015-05-11 Catabasis Pharmaceuticals Inc Conjugados de acidos grasos de estatina y agonistas fxr, composiciones y metodos de uso.
BR112014029245A2 (pt) 2012-05-25 2017-06-27 Catabasis Pharmaceuticals Inc métodos para diminuir a proteína convertase subtilisina/quexina tipo 9 (pcsk9)
AU2014203872A1 (en) 2013-01-07 2015-07-09 Catabasis Pharmaceuticals, Inc. Use of fatty acid niacin conjugates for treating diseases
US20160287712A1 (en) 2013-11-15 2016-10-06 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates

Also Published As

Publication number Publication date
US20140113940A1 (en) 2014-04-24
IN2012DN02661A (member.php) 2015-09-11
US20150209439A1 (en) 2015-07-30
MY158504A (en) 2016-10-14
US8765964B2 (en) 2014-07-01
DK2473045T3 (en) 2016-12-12
CR20120167A (es) 2012-08-21
TWI519312B (zh) 2016-02-01
ES2599626T3 (es) 2017-02-02
GT201200056A (es) 2015-02-11
CN102724877A (zh) 2012-10-10
JP2013503872A (ja) 2013-02-04
KR20120093183A (ko) 2012-08-22
RU2012112461A (ru) 2013-10-10
US20120252850A1 (en) 2012-10-04
TW201117826A (en) 2011-06-01
AU2010289683A1 (en) 2012-04-19
RU2569063C2 (ru) 2015-11-20
US8765963B2 (en) 2014-07-01
US9486534B2 (en) 2016-11-08
SG178948A1 (en) 2012-04-27
US20120264791A1 (en) 2012-10-18
KR101685734B1 (ko) 2016-12-12
AU2010289683C1 (en) 2014-10-16
EP2473045B1 (en) 2016-08-17
AU2010289683B2 (en) 2014-06-12
USRE45275E1 (en) 2014-12-02
US9238077B2 (en) 2016-01-19
CL2010000935A1 (es) 2011-04-15
USRE46605E1 (en) 2017-11-14
NZ599067A (en) 2014-04-30
SG10201500431SA (en) 2015-03-30
US20110053990A1 (en) 2011-03-03
EP2473045A4 (en) 2013-11-20
AR078151A1 (es) 2011-10-19
IL218417A (en) 2017-09-28
BR112012004677A2 (pt) 2020-11-03
US20120184585A1 (en) 2012-07-19
US20140249189A1 (en) 2014-09-04
USRE45261E1 (en) 2014-11-25
EP2473045A1 (en) 2012-07-11
WO2011028689A1 (en) 2011-03-10
CA2772618A1 (en) 2011-03-10
CN102724877B (zh) 2015-05-13
NI201200038A (es) 2012-08-17
US8304551B2 (en) 2012-11-06
US8304552B2 (en) 2012-11-06
US8940903B2 (en) 2015-01-27
US9278136B2 (en) 2016-03-08
IL218417A0 (en) 2012-04-30
US20140228413A1 (en) 2014-08-14
MX2012002710A (es) 2012-04-19
US20180028674A1 (en) 2018-02-01
US20160346397A1 (en) 2016-12-01
JP5802209B2 (ja) 2015-10-28

Similar Documents

Publication Publication Date Title
CA2772618C (en) Fatty acid niacin conjugates and their uses
EP2701509A1 (en) Fatty acid guanidine and salicylate guanidine derivatives and their uses
WO2011044138A1 (en) Lipoic acid acylated salicylate derivatives and their uses
AU2014203872A1 (en) Use of fatty acid niacin conjugates for treating diseases
WO2011044139A1 (en) Fatty acid acifran derivatives and their uses
WO2011044136A1 (en) Fatty acid acipimox derivatives and their uses
US20120252810A1 (en) Fatty acid non-flushing niacin derivatives and their uses
USRE46608E1 (en) Fatty acid niacin conjugates and their uses
HK1173338B (en) Fatty acid niacin conjugates and their uses

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150820

MKLA Lapsed

Effective date: 20210831